NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio Portfolio News / By Karina Tin April 8, 2022 NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio Read More »
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin April 7, 2022 Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Read More »
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors Portfolio News / By Karina Tin April 5, 2022 Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors Read More »
eFFECTOR Therapeutics Announces Transition in Clinical Leadership Portfolio News / By Karina Tin April 4, 2022 eFFECTOR Therapeutics Announces Transition in Clinical Leadership Read More »
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy Portfolio News / By Karina Tin April 1, 2022 Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy Read More »
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Portfolio News / By Karina Tin March 31, 2022 NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Read More »
Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Portfolio News / By Karina Tin March 29, 2022 Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung Read More »
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Portfolio News / By Karina Tin March 29, 2022 Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Read More »
RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis Portfolio News / By Karina Tin March 28, 2022 RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis Read More »
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results Portfolio News / By Karina Tin March 24, 2022 Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results Read More »
